Tenaya Therapeutics Inc

NASDAQ TNYA

Data sourced from

and

Download Data

Tenaya Therapeutics Inc Days Payable Outstanding (DPO) 3 year CAGR for the year ending December 31, 2023: 16.53%

Tenaya Therapeutics Inc Days Payable Outstanding (DPO) 3 year CAGR is 16.53% for the year ending December 31, 2023. The days payables outstanding ratio measures the average number of days it takes for a company to pay its suppliers. It is calculated by dividing accounts payable by the cost of revenue and then multiplying by 365. This ratio indicates the average payment period for suppliers and reflects the efficiency of managing trade payables. A longer period suggests extended payment terms and potential working capital advantages. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Tenaya Therapeutics Inc Days Payable Outstanding (DPO) for the year ending December 31, 2022 was 401.24, a -58.73% change year over year.
Tenaya Therapeutics Inc Days Payable Outstanding (DPO) for the year ending December 31, 2021 was 972.21, a 550.32% change year over year.
Tenaya Therapeutics Inc Days Payable Outstanding (DPO) for the year ending December 31, 2020 was 149.50.

NASDAQ: TNYA

Tenaya Therapeutics Inc

CEO	Mr. Faraz Ali M.B.A.
IPO Date	July 30, 2021
Location	United States
Headquarters	171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Employees	140
Sector	Healthcare
Industry	Biotechnology

Description

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Key trends